Table 1 Patients’ clinical characteristics
Patients’ characteristics | Total N = 57 | Vaccinated N = 14 | Nonvaccinated N = 43 | P value |
|---|---|---|---|---|
Age (years) | ||||
Median [range] | 12.8 [5-18] | 13.3 [6-19] | 12.4 [6-18] | 0.46 |
Gender | ||||
Boys (%) | 39 (70) | 11 (78) | 28 (65) | 0.51 |
Girls (%) | 18 (30) | 3 (22) | 15 (35) | |
Age at the time of diagnosis (years) | ||||
Median [range] | 3.3 [1-7] | 3 [1-6] | 3.4 [1-7] | 0.60 |
Duration of illness (years) | ||||
Median [range] | 9.05 [3-16] | 9.78 [3-16] | 8.72 [3-16] | 0.12 |
Current immunosuppressive treatment | 42 (74) | 11 (78) | 31 (72) | 0.73 |
Prednisone | 9 | 1 | 8 | 0.43 |
Prednisone + tacrolimus | 1 | 0 | 1 | 0.22 |
Prednisone + mycophenolate | 15 | 6 | 9 | 1 |
Prednisone + ciclosporine | 3 | 1 | 2 | 1 |
Prednisone + levamisole | 2 | 0 | 2 | 1 |
Prednisone + tacrolimus + mycophenolate | 5 | 1 | 4 | 1 |
Rituximab | 1 | 1 | 0 | 0.25 |
Mycophenolate | 6 | 1 | 5 | 1 |
No Treatment | 15 (26) | 3 (22) | 12 (28) | 0.89 |
Relapses | ||||
During the six months prior to vaccination and/or flu season | 18 (31) | 5 (36) | 13 (30) | 0.74 |
During the six months following vaccination and/or during flu season | 15 (26) | 1 (7) | 13 (30) | 0.31 |